News Can Gilead find another Pharmasset in 2017? Company needs to make acquisition to grow, admits CEO.
News New Gilead and AbbVie hepatitis C combos filed in EU Companies aim to cut treatment time and side effects.
News Pharma criticises 'heavy handed' NICE affordability test NHS England and NICE are attempting to reduce budget impact of drugs.
Views & Analysis The future of healthcare: the patient advocate and investor ... Examining the views of different stakeholders in the ecosystem supporting drug R&D.
News Biogen courts controversy with $750k-a-year rare disease dru... Biogen's SMA treatment approved - but price is $125,000 per dose
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends